Stoke Therapeutics
STOK
106 hedge funds and large institutions have $1.49B invested in Stoke Therapeutics in 2021 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 32 increasing their positions, 25 reducing their positions, and 13 closing their positions.
100% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 13
28% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 25
14% more funds holding
Funds holding: 93 → 106 (+13)
2.63% less ownership
Funds ownership: 107.44% → 104.81% (-2.6%)
33% less call options, than puts
Call options by funds: $3M | Put options by funds: $4.46M
38% less capital invested
Capital invested by funds: $2.39B → $1.49B (-$901M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$17.8M |
| 2 |
Morgan Stanley
New York
|
+$11.7M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$8.58M |
| 4 |
Two Sigma Investments
New York
|
+$5.83M |
| 5 |
RI
RTW Investments
New York
|
+$5.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$41.2M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$11.7M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$8.09M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$7.82M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.2M |
STOK Hedge Fund Activity: Q1 2021 in Review
106 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q1 2021, worth a combined $1.49B — down 38% from $2.39B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new STOK positions and 13 closed out — a net gain of 13 holders — while 32 added to existing stakes and 25 trimmed.
The largest buyer was State Street, adding an estimated $17.8M. The largest seller was Fidelity Investments, cutting an estimated $41.2M.
- 106 institutional investors held Stoke Therapeutics (STOK) as of Q1 2021, up from 93 in Q4 2020.
- Funds reported $1.49B of Stoke Therapeutics stock for Q1 2021, down 38% quarter-over-quarter.
- 26 funds opened new Stoke Therapeutics positions in Q1 2021 and 13 closed out, a net change of +13 holders.
- The largest Stoke Therapeutics buyer in Q1 2021 was State Street, an estimated $17.8M added.
- The largest Stoke Therapeutics seller in Q1 2021 was Fidelity Investments, an estimated $41.2M sold.
Based on aggregated 13F filings for Q1 2021.